Overview

Marched Pair Study Conventional Doxorubicin(DOX) Versus Pegylated Liposomal Doxorubicin(PLD) Neoadjuvant Chemotherapy

Status:
Unknown status

Trial end date:
2020-11-01

Target enrollment:

Participant gender:

Summary

The regimen PLD plus cyclophosphamide 4 cycles followed by paclitaxel or docetaxel 4 cycles(noted in phase II CAPRICE) will be used as experimental group. The regimen will be compared to the standard treatment of doxorubicin plus cyclophosphamide(AC) 4 cycles followed by paclitaxel or docetaxel 4 cycles[noted in National Comprehensive Cancer Network (NCCN) guideline].

Phase:

Phase 2

Details

Lead Sponsor:

Jilin University

Treatments:

Cyclophosphamide
Dexrazoxane
Docetaxel
Doxorubicin
Liposomal doxorubicin
Pirarubicin
Razoxane
Vitamin B Complex
Vitamins